Skip to main content

M-tron Industries, Inc.

For the period ended Aug 12, 2026. Filed Aug 12, 2026.

View on SEC.gov

About this filing

A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.

Aug 12, 2026 · Filed Aug 12, 2026

Use the contents to explore the available documents and sections.

MPTI$60.34+5.3%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the****Securities Exchange Act of 1934

Date of report (Date of earliest event reported):August 12, 2026

M-tron Industries, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware001-4139146-0457994
(State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
2525 Shader Road, Orlando, FL32804
(Address of Principal Executive Offices)(Zip Code)

(407)298-2000

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01MPTINYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Item 2.02.Results of Operations and Financial Condition

On August 12, 2026, M-tron Industries, Inc. ("Mtron" or the "Company") reported its financial results for the three and six months ended June 30, 2026. A copy of the press release containing this information is furnished as Exhibit 99.1 hereto and is incorporated by reference in this Item 2.02.

Item 7.01.Regulation FD Disclosure

Management, including Mtron's Chief Executive Officer, Cameron Pforr, will host a conference call with the investment community on Thursday August 13, 2026, to discuss the Company's second quarter 2026 results and to answer investor questions.

The call will begin at 10:30 am Eastern Time (U.S. and Canada) on Thursday August 13, 2026, and can be accessed using the dial-in details below:

Toll Free Dial-in Number:+1 833 461 5787
Toll Dial-in Number:+1 585 542 9983
Conference ID:466 106 739
Webcast URL:https://events.q4inc.com/attendee/466106739
Item 9.01.Financial Statements and Exhibits

(d)Exhibits

Exhibit No.Description
99.1Press Release of M-tron Industries, Inc. dated August 12, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

M-TRON INDUSTRIES, INC.
(Registrant)
Date: August 12, 2026By:/s/ Cameron Pforr
Name:Cameron Pforr
Title:Chief Executive Officer
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.